Hikma Pharmaceuticals (LON:HIK) Shares Cross Above 200-Day Moving Average - Should You Sell?

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 2,016.45 ($26.10) and traded as high as GBX 2,034 ($26.33). Hikma Pharmaceuticals shares last traded at GBX 2,010 ($26.02), with a volume of 35,338,895 shares.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Berenberg Bank reissued a "buy" rating and issued a GBX 2,560 ($33.13) target price on shares of Hikma Pharmaceuticals in a research report on Monday, March 10th. JPMorgan Chase & Co. reiterated an "overweight" rating on shares of Hikma Pharmaceuticals in a report on Friday, March 7th.

Hikma Pharmaceuticals Trading Down 1.5 %

The company's 50 day simple moving average is GBX 2,174.12 and its 200 day simple moving average is GBX 2,016.58. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The firm has a market cap of £5.45 billion, a price-to-earnings ratio of 19.30, a P/E/G ratio of 2.38 and a beta of 0.41.

Hikma Pharmaceuticals Increases Dividend

The business also recently announced a dividend, which will be paid on Thursday, May 1st. Investors of record on Thursday, March 20th will be paid a dividend of $0.48 per share. This represents a yield of 1.8%. This is a boost from Hikma Pharmaceuticals's previous dividend of $0.32. The ex-dividend date of this dividend is Thursday, March 20th. Hikma Pharmaceuticals's payout ratio is presently 60.84%.

Remove Ads

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.